A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Phase 1 Recruiting 112 enrolled International AIDS Vaccine Initiative Biomedical Advanced Research and Development Authority · collab

RandomizedSingle-groupTriple-blindPrevention

Summary

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Timeline

Start: 2026-03-27
Primary completion: 2027-11
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rVSV∆G-MARV-GP	Vaccine	—	—

A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Summary

Timeline

Drugs

Indications